Advertisement

Tumor Biology

, Volume 35, Issue 3, pp 2461–2471 | Cite as

Bufalin exerts antitumor effects by inducing cell cycle arrest and triggering apoptosis in pancreatic cancer cells

Research Article

Abstract

As one of the most aggressive human malignancies, pancreatic cancer is a leading cause of cancer-related deaths worldwide and only about 4 % of patients will live 5 years after diagnosis. Eighty to approximately eighty-five percent of patients are diagnosed with an unresectable or metastatic disease, which is correlated with poor prognosis and low survival rate. Therefore, it is tremendously significant to exploit novel chemicals to prevent and treat pancreatic cancer. Previous research and clinical studies have demonstrated that many natural products derived from traditional Chinese medicine (TCM) such as camptothecin derivatives and vinca alkaloids could be effective antitumor compounds, hinting that TCM is a promising source for developing new antitumor drugs. In this report, we investigated the effects of bufalin, a primary active ingredient of the traditional Chinese medicine Chan-Su, on pancreatic cancer cell lines PANC-1 and CFPAC-1 and studied the underlying molecular mechanism. We found that exposure to bufalin could suppress the proliferation of pancreatic cancer cells time and dose dependently. We used flow cytometry to study the effects of bufalin on apoptosis and cell cycle distribution in PANC-1 and CFPAC-1 cells. The results indicated that bufalin could significantly induce both apoptosis and G2/M cell cycle arrest in pancreatic cancer cells. With western blotting, we found that the expression level of an antiapoptotic protein heat shock protein 27 (Hsp27) and its partner molecule p-Akt was decreased upon the treatment with bufalin. Besides, bufalin activated pro-caspase-3 and pro-caspase-9 and modulated the expression level of Bcl-2 and Bax. These data suggested that bufalin may trigger apoptosis by targeting Hsp27, which could inhibit apoptosis by interfering with key apoptotic proteins. The influence on the level of cylinB1, CDK1, and p21 was also observed after bufalin treatment, and the relationship between Hsp27 and the cell cycle-related proteins mentioned above deserves much more research. In addition, our data showed that bufalin could enhance the growth inhibition effect of gemcitabine in above pancreatic cancer cells. Taken together, bufalin might be worthy of further study for its potential as a therapeutic agent for pancreatic cancer treatment.

Keywords

Pancreatic cancer Bufalin Antitumor Cell cycle arrest Apoptosis Hsp27 

Notes

Acknowledgments

This study was supported by the National Natural Science Foundation of China (81201934, 81100645), Specialized Research Fund for the Doctoral Program of Higher Education (20120131120061), China Postdoctoral Science Foundation (2013 M531612) and Independent Innovation Foundation of Shandong University (2012TS155).

Conflicts of interest

None

References

  1. 1.
    Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607–20.PubMedCrossRefGoogle Scholar
  2. 2.
    Guo X, Cui Z. Current diagnosis and treatment of pancreatic cancer in China. Pancreas. 2005;31:13–22.PubMedCrossRefGoogle Scholar
  3. 3.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 2013;63:11–30.PubMedCrossRefGoogle Scholar
  4. 4.
    Duffy JP, Eibl G, Reber HA, Hines OJ. Influence of hypoxia and neoangiogenesis on the growth of pancreatic cancer. Mol Cancer. 2003;2:12.PubMedCentralPubMedCrossRefGoogle Scholar
  5. 5.
    Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997;15:2403–13.PubMedGoogle Scholar
  6. 6.
    Colucci G, Giuliani F, Gebbia V, Biglietto M, Rabitti P, Uomo G, et al. Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase III study of the Gruppo Oncologia dell'Italia Meridionale. Cancer. 2002;94:902–10.PubMedCrossRefGoogle Scholar
  7. 7.
    Colucci G, Labianca R, Di Costanzo F, Gebbia V, Carteni G, Massidda B, et al. Randomized phase III trial of gemcitabine plus cisplatin compared with single-agent gemcitabine as first-line treatment of patients with advanced pancreatic cancer: the gip-1 study. J Clin Oncol. 2010;28:1645–51.PubMedCrossRefGoogle Scholar
  8. 8.
    Cunningham D, Chau I, Stocken DD, Valle JW, Smith D, Steward W, et al. Phase III randomized comparison of gemcitabine versus gemcitabine plus capecitabine in patients with advanced pancreatic cancer. J Clin Oncol. 2009;27:5513–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2007;25:1960–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, et al. Folfirinox versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817–25.PubMedCrossRefGoogle Scholar
  11. 11.
    Von Hoff D, Ervin TJ, Arena FP, Chiorean EG, Infante JR, Moore MJ, Seay TE, Tjulandin S, Ma WW, Saleh MN: Randomized phase III study of weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic adenocarcinoma of the pancreas (MPACT): 2013 ASCO Gastrointestinal Cancers Symposium, Abstract, 2012, 148, pp 24–26Google Scholar
  12. 12.
    Maitra A, Hruban RH. Pancreatic cancer. Annu Rev Pathol. 2008;3:157–88.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Xie XB, Yin JQ, Wen LL, Gao ZH, Zou CY, Wang J, et al. Critical role of heat shock protein 27 in bufalin-induced apoptosis in human osteosarcomas: a proteomic-based research. PLoS One. 2012;7:16.Google Scholar
  14. 14.
    Xie CM, Chan WY, Yu S, Zhao J, Cheng CH. Bufalin induces autophagy-mediated cell death in human colon cancer cells through reactive oxygen species generation and jnk activation. Free Radic Biol Med. 2011;51:1365–75.PubMedCrossRefGoogle Scholar
  15. 15.
    Zhu Z, Li E, Liu Y, Gao Y, Sun H, Wang Y, et al. Bufalin induces the apoptosis of acute promyelocytic leukemia cells via the downregulation of survivin expression. Acta Haematol. 2012;128:144–50.PubMedCrossRefGoogle Scholar
  16. 16.
    Hsiao YP, Yu CS, Yu CC, Yang JS, Chiang JH, Lu CC, et al. Triggering apoptotic death of human malignant melanoma a375.S2 cells by bufalin: involvement of caspase cascade-dependent and independent mitochondrial signaling pathways. Evid Based Complement Alternat Med. 2012;591241:7.Google Scholar
  17. 17.
    Yan S, Qu X, Xu C, Zhu Z, Zhang L, Xu L, et al. Down-regulation of cbl-b by bufalin results in up-regulation of dr4/dr5 and sensitization of trail-induced apoptosis in breast cancer cells. J Cancer Res Clin Oncol. 2012;138:1279–89.PubMedCrossRefGoogle Scholar
  18. 18.
    Li D, Qu X, Hou K, Zhang Y, Dong Q, Teng Y, et al. Pi3k/akt is involved in bufalin-induced apoptosis in gastric cancer cells. Anticancer Drugs. 2009;20:59–64.PubMedCrossRefGoogle Scholar
  19. 19.
    Yu CH, Kan SF, Pu HF. Jea Chien E, Wang PS: Apoptotic signaling in bufalin- and cinobufagin-treated androgen-dependent and -independent human prostate cancer cells. Cancer Sci. 2008;99:2467–76.PubMedCrossRefGoogle Scholar
  20. 20.
    Takai N, Ueda T, Nishida M, Nasu K, Narahara H. Bufalin induces growth inhibition, cell cycle arrest and apoptosis in human endometrial and ovarian cancer cells. Int J Mol Med. 2008;21:637–43.PubMedGoogle Scholar
  21. 21.
    Huang WW, Yang JS, Pai SJ, Wu PP, Chang SJ, Chueh FS, et al. Bufalin induces g(0)/g(1) phase arrest through inhibiting the levels of cyclin d, cyclin e, cdk2 and cdk4, and triggers apoptosis via mitochondrial signaling pathway in t24 human bladder cancer cells. Mutat Res. 2012;732:26–33.PubMedCrossRefGoogle Scholar
  22. 22.
    Zhu Z, Sun H, Ma G, Wang Z, Li E, Liu Y. Bufalin induces lung cancer cell apoptosis via the inhibition of pi3k/akt pathway. Int J Mol Sci. 2012;13:2025–35.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Concannon CG, Gorman AM, Samali A. On the role of hsp27 in regulating apoptosis. Apoptosis. 2003;8:61–70.PubMedCrossRefGoogle Scholar
  24. 24.
    Ischia J, Saad F, Gleave M. The promise of heat shock protein inhibitors in the treatment of castration resistant prostate cancer. Curr Opin Urol. 2013;23:194–200.PubMedCrossRefGoogle Scholar
  25. 25.
    Zimmermann M, Nickl S, Lambers C, Hacker S, Mitterbauer A, Hoetzenecker K, et al. Discrimination of clinical stages in non-small cell lung cancer patients by serum hsp27 and hsp70: a multi-institutional case–control study. Clin Chim Acta. 2012;413:1115–20.PubMedCrossRefGoogle Scholar
  26. 26.
    Kapranos N, Kominea A, Konstantinopoulos PA, Savva S, Artelaris S, Vandoros G, et al. Expression of the 27-kda heat shock protein (hsp27) in gastric carcinomas and adjacent normal, metaplastic, and dysplastic gastric mucosa, and its prognostic significance. J Cancer Res Clin Oncol. 2002;128:426–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Olejek A, Damasiewicz-Bodzek A, Bodzek P, Wielkoszynski T, Zamlynski J, Stoltny P, et al. Concentrations of antibodies against heat shock protein 27 in the sera of women with ovarian carcinoma. Int J Gynecol Cancer. 2009;19:1516–20.PubMedCrossRefGoogle Scholar
  28. 28.
    Yang L, Cao L, Yang M, Tang D, Kang R, Min X, et al. Hsp27: A novel therapeutic target for pediatric m4/m5 acute myeloid leukemia. Oncol Rep. 2013;29:1459–66.PubMedGoogle Scholar
  29. 29.
    Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, et al. Protein profiling of microdissected pancreas carcinoma and identification of hsp27 as a potential serum marker. Clin Chem. 2007;53:629–35.PubMedCrossRefGoogle Scholar
  30. 30.
    Schafer C, Seeliger H, Bader DC, Assmann G, Buchner D, Guo Y, et al. Heat shock protein 27 as a prognostic and predictive biomarker in pancreatic ductal adenocarcinoma. J Cell Mol Med. 2012;16:1776–91.PubMedCrossRefGoogle Scholar
  31. 31.
    Liu QH, Zhao CY, Zhang J, Chen Y, Gao L, Ni CY, et al. Role of heat shock protein 27 in gemcitabine-resistant human pancreatic cancer: comparative proteomic analyses. Mol Med Rep. 2012;6:767–73.PubMedGoogle Scholar
  32. 32.
    Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Taba K, Fujimoto M, Okita K, et al. A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Rep. 2008;1:429–34.PubMedGoogle Scholar
  33. 33.
    Taba K, Kuramitsu Y, Ryozawa S, Yoshida K, Tanaka T, Mori-Iwamoto S, et al. Knk437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine. Chemotherapy. 2011;57:12–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Baylot V, Andrieu C, Katsogiannou M, Taieb D, Garcia S, Giusiano S, et al. Ogx-427 inhibits tumor progression and enhances gemcitabine chemotherapy in pancreatic cancer. Cell Death Dis. 2011;20:104.Google Scholar
  35. 35.
    Mori-Iwamoto S, Taba K, Kuramitsu Y, Ryozawa S, Tanaka T, Maehara S, et al. Interferon-gamma down-regulates heat shock protein 27 of pancreatic cancer cells and helps in the cytotoxic effect of gemcitabine. Pancreas. 2009;38(2):224–6. doi: 10.1097/MPA.0b013e3181773970.PubMedCrossRefGoogle Scholar
  36. 36.
    Zhang X, Liu Z, Xu B, Sun Z, Gong Y, Shao C. Neferine, an alkaloid ingredient in lotus seed embryo, inhibits proliferation of human osteosarcoma cells by promoting p38 mapk-mediated p21 stabilization. Eur J Pharmacol. 2012;677:47–54.PubMedCrossRefGoogle Scholar
  37. 37.
    Jiang Y, Zhang Y, Luan J, Duan H, Zhang F, Yagasaki K, et al. Effects of bufalin on the proliferation of human lung cancer cells and its molecular mechanisms of action. Cytotechnology. 2010;62:573–83.PubMedCentralPubMedCrossRefGoogle Scholar
  38. 38.
    Zhu Z, Li E, Liu Y, Gao Y, Sun H, Ma G, et al. Inhibition of jak-stat3 pathway enhances bufalin-induced apoptosis in colon cancer sw620 cells. World J Surg Oncol. 2012;10:1477–7819.Google Scholar
  39. 39.
    Hong SH, Choi YH. Bufalin induces apoptosis through activation of both the intrinsic and extrinsic pathways in human bladder cancer cells. Oncol Rep. 2012;27:114–20.PubMedGoogle Scholar
  40. 40.
    Qi F, Inagaki Y, Gao B, Cui X, Xu H, Kokudo N, et al. Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via fas- and mitochondria-mediated pathways. Cancer Sci. 2011;102:951–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Xie CM, Liu XY, Yu S, Cheng CH. Cardiac glycosides block cancer growth through hif-1alpha- and nf-kappab-mediated plk1. Carcinogenesis. 2013;34:1870–80.PubMedCrossRefGoogle Scholar
  42. 42.
    Garrido C, Schmitt E, Cande C, Vahsen N, Parcellier A, Kroemer G. Hsp27 and hsp70: potentially oncogenic apoptosis inhibitors. Cell Cycle. 2003;2:579–84.PubMedCrossRefGoogle Scholar
  43. 43.
    Pandey P, Farber R, Nakazawa A, Kumar S, Bharti A, Nalin C, et al. Hsp27 functions as a negative regulator of cytochrome c-dependent activation of procaspase-3. Oncogene. 2000;19:1975–81.PubMedCrossRefGoogle Scholar
  44. 44.
    Garrido C, Bruey JM, Fromentin A, Hammann A, Arrigo AP, Solary E. Hsp27 inhibits cytochrome c-dependent activation of procaspase-9. Faseb J. 1999;13:2061–70.PubMedGoogle Scholar
  45. 45.
    Rane MJ, Pan Y, Singh S, Powell DW, Wu R, Cummins T, et al. Heat shock protein 27 controls apoptosis by regulating akt activation. J Biol Chem. 2003;278:27828–35.PubMedCrossRefGoogle Scholar
  46. 46.
    Guo K, Kang NX, Li Y, Sun L, Gan L, Cui FJ, et al. Regulation of hsp27 on nf-kappab pathway activation may be involved in metastatic hepatocellular carcinoma cells apoptosis. BMC cancer. 2009;9:1471–2407.CrossRefGoogle Scholar
  47. 47.
    Hardwick JM, Soane L. Multiple functions of bcl-2 family proteins. Cold Spring Harb Perspect Biol. 2013;5(2). doi: 10.1101/cshperspect.a008722.
  48. 48.
    Collins K, Jacks T, Pavletich NP. The cell cycle and cancer. Proc Natl Acad Sci U S A. 1997;94(7):2776–8.PubMedCentralPubMedCrossRefGoogle Scholar
  49. 49.
    Chen T, Stephens PA, Middleton FK, Curtin NJ. Targeting the s and g2 checkpoint to treat cancer. Drug Discov Today. 2012;17:194–202.PubMedCrossRefGoogle Scholar
  50. 50.
    Bucher N, Britten CD. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br J Cancer. 2008;98:523–8.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432:316–23.PubMedCrossRefGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2013

Authors and Affiliations

  1. 1.Department of Medical Oncology, Cancer Center, Qilu HospitalShandong UniversityJinanChina
  2. 2.Department of OphthalmologyQilu Hospital of Shandong UniversityJinanChina
  3. 3.Department of Medical Genetics, Key Laboratory for Experimental Teratology of the Ministry of EducationShandong University School of MedicineJinanChina

Personalised recommendations